101 
Market Cap
As of July 16, 2010: $273,264,000.00
Stock Chart
Sirtex - 30 Day Poll
Recent BLOGS About Sirtex Add New
There are no blogs to display.
Latest Company News
|
Sirtex Medical Limited Invests In Major New Asia Pacific Study To Expand Clinical Use
Reuters Key Development - Jun 24, 2010 |
|
Sirtex Medical Limited Announces Positive Results From Asian Clinical Trial
Reuters Key Development - Jun 8, 2010 |
|
Sirtex Medical Limited Announces Interest Of Platypus Asset Management
Reuters Key Development - Mar 19, 2010 |
|
Sirtex Medical & Oxford University to test new bowel cancer therapy
Proactive Investors Australia - Mar 1, 2010 Oncology-focussed treatment company Sirtex Medical (ASX: SRX) today announced the start of a new trial to see if chemotherapy used with SIR-Spheres® microspheres targeted radiation therapy, is ...
|
|
Sirtex Medical Limited Announces New Uk Trial With Oxford University To Test New Bowel Cancer Therapy
Reuters Key Development - Mar 1, 2010 |
|
Sirtex Medical Limited Joins Bayer Healthcare In European Liver Cancer Trial
Reuters Key Development - Feb 10, 2010 |
|
Sirtex Appoints Michael Mangano to Lead U.S. Operations
Business Wire - Jan 19, 2010 WILMINGTON, Mass.--(BUSINESS WIRE)--Sirtex, a leading developer of targeted and innovative cancer therapies, announces the appointment of Michael Mangano as President of Sirtex Medical, Inc. Mr ...
|
Website
Videos related to Sirtex
Company Profile
Sirtex is a profitable biotech generating real cashflow and founded in 1997. It has developed a treatment for liver cancer, which is the fifth most widespread cancer.
Patients are injected with a small particle in a process called selective internal radiation therapy. The particles are less than the width of a human hair and are injected into the hepatic artery, lodging themselves in the tumour and delivering concise high doses of radiation.
An international trend of sales has begun with a move into Asia and ongoing penetration in the biggest markets i.e. US and Europe.
Cash on hand: $26.7M in 2009 and no debt.
Revenue increased by 72 per cent in teh last annual period to $65.6 million.
Terms & Rules
As per ASIC Regulatory Guide 162: All investment tips and comments appearing on this website (Poll results, BLOGS & discussion forums) are submitted by the general public who are not licensed financial advisors. None of the information on this website is financial or investment advice, you should seek independent financial or investment advice by a licensed financial or investment advisor before entering into any position of financial risk. Before using this website, you must agree to the BioInvesting.com.au Terms Of Use